Bring together the field’s top scientists to conduct big, bold research that gets to patients faster.
In April 2016, the Parker Foundation announced a $250 million grant to establish the Parker Institute for Cancer Immunotherapy. For decades, entrenched infrastructure barriers have slowed progress in the fight against cancer and the development of potent immunotherapies. The Parker Institute breaks down these barriers. The result is a groundbreaking new research and intellectual property model that builds collaboration between researchers, nonprofits and industry all working together to get treatments to patients faster.
“To do the research that really moves the field forward, you need a lot of collaboration, but you also need one big, open sandbox for everyone to play in, in order for that collaboration to take place.”
Sean Parker, Chairman
The Parker Institute for Cancer Immunotherapy builds upon the foundation’s leadership in funding and promoting research. It reflects 10 years of support for immunotherapy research by Sean Parker, including his backing of the Stand Up to Cancer and Cancer Research Institute Immunotherapy Dream Team. In 2013, Parker was awarded the Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research by the Cancer Research Institute.
Our flexible model enables us to work with researchers in a variety of ways so we can empower them to do their best science. We started the program by providing institutional support to six academic centers, which are pioneers in the cancer immunotherapy space, including Memorial Sloan Kettering Cancer Center; Stanford Medicine; the University of California, Los Angeles; the University of California, San Francisco; the University of Pennsylvania and The University of Texas MD Anderson Cancer Center. More recently, we initiated new programmatic support for outstanding investigators, including a talented group of researchers at Dana-Farber Cancer Institute, Robert Schreiber, PhD, of Washington University School of Medicine in St. Louis, Nina Bhardwaj, MD, PhD, of the Icahn School of Medicine at Mount Sinai and Philip Greenberg, MD, of the Fred Hutchinson Cancer Research Center. We believe that this multifaceted approach to bring the best and brightest minds in basic and translational research will accelerate the development of cancer immunotherapies with the greatest chance of impact on patients.
Scientific Steering Committee
Founding Chief Executive Officer and Vice Chairman of the Board of Directors at GRAIL, Inc.
Elizabeth M. Jaffee, MD
Deputy Director, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Professor of Oncology
Daniel Littman, MD, PhD
Helen L. and Martin S. Kimmel Professor of Molecular Immunology, New York University